Key findings at 24 weeks: LDL-C: 58.2% vs +2.6% with placebo NonHDL-C: 52.3% ApoB: 48.2% Lp(a): 24.7% Results were sustained at 52 weeks, with a safety profile comparable to placebo
Neurological symptoms often develop gradually and may include: Paraesthesia : tingling or 'pins and needles' sensations, typically starting in the feet and hands Numbness : reduced sensation in the extremities, which may affect balance and coordination Burning pain : particularly in the feet, often worse at night Weakness : muscle weakness and difficulty walking Balance problems : unsteady gait and increased fall risk due to proprioceptive impairment Cognitive changes : memory problems, confusion, difficulty concentrating, and mood disturbances Haematological signs may accompany neurological symptoms and include fatigue, weakness, pallor, and shortness of breath due to megaloblastic anaemia
This is typically reversible with dose reduction or discontinuation
What you may notice: Clothes fitting differently More control around food Decreased cravings Boosted confidence What your medical weight loss plan includes: Dose evaluation (only if needed we never rush titration) Review of digestion, hydration, and movement Reinforcement of balanced nutrition Week 3 priority: Avoiding undereating, which is common but not helpful
